Featured Research

from universities, journals, and other organizations

Targeting The More Lethal Form Of The Cancer Rhabdomyosarcoma

Date:
May 26, 2009
Source:
Journal of Clinical Investigation
Summary:
Embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS) are the most common forms of an aggressive muscle cancer that mostly affects children. Although ARMS is less common than ERMS, it is associated with a much higher rate of mortality. New research, showing that the protein ILK promotes the growth of ARMS cells but suppresses the growth of ERMS cells, provides hope that developing a therapy tailored to the ARMS form of the cancer might be possible.

Rhabdomyosarcoma (RMS) is an aggressive muscle cancer that mostly affects children. The most common forms of RMS are embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS). Although ARMS is less common than ERMS, it is associated with a much higher rate of mortality. A therapy tailored to the ARMS form of RMS is therefore badly needed.

Related Articles


A team of researchers, at the Hospital for Sick Children, Toronto, and Monash Institute of Medical Research, Australia, has now provided hope that it might be possible to develop such a therapy by showing that the protein ILK promotes the growth of ARMS cells, whereas it suppresses the growth of ERMS cells.

The team, led by David Malkin and Gregory Hannigan, determined that the signaling protein JNK mediated these differing effects of ILK. Knocking down expression of ILK in ERMS cells induced activation of JNK and promoted tumor cell growth both in vitro and when the cells were transplanted into immunodeficient mice. Conversely, knocking down expression of ILK in ARMS cells abrogated both JNK signaling and tumor cell growth. Further analysis revealed that the protein product of the fusion gene that characterizes ARMS downregulated JNK1 expression, providing mechanistic insight into the opposing roles of ILK in ARMS and ERMS. The authors therefore suggest it should be possible to identify patients with ARMS who would benefit from an anticancer therapeutic that targets ILK.

In an accompanying commentary, Charles Keller and colleagues concur with the authors that targeting ILK might provide a therapeutic strategy tailored to the treatment of ARMS. However, they caution that further studies are needed, in part because of the high rate of misdiagnosis of ARMS versus ERMS.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Adam D. Durbin et al. JNK1 determines the oncogenic or tumorsuppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. Journal of Clinical Investigation, May 26, 2009

Cite This Page:

Journal of Clinical Investigation. "Targeting The More Lethal Form Of The Cancer Rhabdomyosarcoma." ScienceDaily. ScienceDaily, 26 May 2009. <www.sciencedaily.com/releases/2009/05/090526093938.htm>.
Journal of Clinical Investigation. (2009, May 26). Targeting The More Lethal Form Of The Cancer Rhabdomyosarcoma. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2009/05/090526093938.htm
Journal of Clinical Investigation. "Targeting The More Lethal Form Of The Cancer Rhabdomyosarcoma." ScienceDaily. www.sciencedaily.com/releases/2009/05/090526093938.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins